Oncology Pharmaceuticals Market in India 2014
The report is sent in 0-2 business days after order is placed.
Netscribes’ latest market research report titled Oncology Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing number of cancer cases are the key drivers of this market. Lung, stomach, colon and breast cancer cause the maximum number of cancer deaths each year. Pharmaceutical companies are progressively increasing R&D expenditure on cancer vaccines. The growing number of patients seeking treatment for cancer has made hospitals realize that cancer treatment is an important area for growth. Gleevec, Mabthera, Iressa, Avastin, Grafeel, Soliris and Herceptin are the top selling cancer drugs in the Indian market.
Alternative therapies such as cancer gene therapy and cancer cell therapy are increasingly becoming popular in cases where conventional therapies have failed. Combination therapies are being increasingly used in cancer treatments. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of Oncological drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Manufacture of generic oncology drugs will help the pharmaceutical manufacturer gain a competitive advantage over others in a highly competitive pharma market. Companies should focus on development of new molecules in order to prolong the longevity of a blockbuster drug in the market.
Netscribes’ latest market research report titled Oncology Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing number of cancer cases are the key drivers of this market. Lung, stomach, colon and breast cancer cause the maximum number of cancer deaths each year. Pharmaceutical companies are progressively increasing R&D expenditure on cancer vaccines. The growing number of patients seeking treatment for cancer has made hospitals realize that cancer treatment is an important area for growth. Gleevec, Mabthera, Iressa, Avastin, Grafeel, Soliris and Herceptin are the top selling cancer drugs in the Indian market.
Alternative therapies such as cancer gene therapy and cancer cell therapy are increasingly becoming popular in cases where conventional therapies have failed. Combination therapies are being increasingly used in cancer treatments. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of Oncological drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Manufacture of generic oncology drugs will help the pharmaceutical manufacturer gain a competitive advantage over others in a highly competitive pharma market. Companies should focus on development of new molecules in order to prolong the longevity of a blockbuster drug in the market.
Slide 1: Executive Summary
Macroeconomic Indicators
Slide 2: GDP at Factor Cost: Quarterly (2010-11, 2011-12, 2012-13, 2013-14), Inflation Rate: Monthly (Jul 2013 – Dec 2013)
Slide 3: Gross Fiscal Deficit: Monthly (Feb 2013 – Jul 2013), Exchange Rate: Half Yearly (Oct 2013 – Mar 2014)
Slide 4: Lending Rate: Annual (2008-09, 2009-10, 2010-11, 2011-12), Trade Balance: Annual (2010-11, 2011-12, 2012-13, 2013-14), FDI: Annual (2009-10, 2010-11, 2011-12, 2012-13)
Introduction
Slide 5-6: Types of Chemotherapy drugs
Market Overview
Slide 7-9: Global Oncology Pharmaceutical Market – Overview, Market Size & Growth (2013-2018e), Indian Oncology Pharmaceutical Market – Overview, Market Size & Growth (2013-2018e), Regions with high cancer prevalence, Top 5 cancer’s in India
Export-Import
Slide 10-11: Region wise Exports, Total Exports, Region wise Imports, Total Imports
Value Chain
Slide 12-13: Market Value Chain Analysis
Drivers & Challenges
Slide 14: Drivers and Challenges – Summary
Slide 15-19: Drivers
Slide 20-22: Challenges
Government Initiatives
Slide 23: Government Initiatives – Summary
Slide 24: Helping the Market to grow
Slide 25: National List of Essential Medicines (NLEM), Jan Aushadhi Stores (JAS)
Slide 26-27: cancer awareness programmes
Slide 28: Reduction in Excise Duties
Regulations
Slide 29: Licensing and registration of pharmaceuticals
Slide 30: Various other regulatory frameworks
Slide 31-33: Patent Approvals
Competitive Landscape
Slide 34: Porter’s Five Forces Analysis
Slide 35: Public Trading Comparables, Top 3 Companies
Slide 36-38: Competitive Benchmarking, Key Ratios of Top 3 Companies – Operational Basis (FY 2013)
Slide 39: Competitive Benchmarking, Key Ratios of Top 3 Companies – Financial Basis (FY 2013)
Slide 40-75: Major Public Players
Slide 76-85: major Private Players
Recent Developments
Slide 86-87: Recent Developments
Strategic Recommendation
Slide 88: Strategic recommendation
Appendix
Slide 89: Key Ratios Description
Slide 90: Sources of Information
Macroeconomic Indicators
Slide 2: GDP at Factor Cost: Quarterly (2010-11, 2011-12, 2012-13, 2013-14), Inflation Rate: Monthly (Jul 2013 – Dec 2013)
Slide 3: Gross Fiscal Deficit: Monthly (Feb 2013 – Jul 2013), Exchange Rate: Half Yearly (Oct 2013 – Mar 2014)
Slide 4: Lending Rate: Annual (2008-09, 2009-10, 2010-11, 2011-12), Trade Balance: Annual (2010-11, 2011-12, 2012-13, 2013-14), FDI: Annual (2009-10, 2010-11, 2011-12, 2012-13)
Introduction
Slide 5-6: Types of Chemotherapy drugs
Market Overview
Slide 7-9: Global Oncology Pharmaceutical Market – Overview, Market Size & Growth (2013-2018e), Indian Oncology Pharmaceutical Market – Overview, Market Size & Growth (2013-2018e), Regions with high cancer prevalence, Top 5 cancer’s in India
Export-Import
Slide 10-11: Region wise Exports, Total Exports, Region wise Imports, Total Imports
Value Chain
Slide 12-13: Market Value Chain Analysis
Drivers & Challenges
Slide 14: Drivers and Challenges – Summary
Slide 15-19: Drivers
Slide 20-22: Challenges
Government Initiatives
Slide 23: Government Initiatives – Summary
Slide 24: Helping the Market to grow
Slide 25: National List of Essential Medicines (NLEM), Jan Aushadhi Stores (JAS)
Slide 26-27: cancer awareness programmes
Slide 28: Reduction in Excise Duties
Regulations
Slide 29: Licensing and registration of pharmaceuticals
Slide 30: Various other regulatory frameworks
Slide 31-33: Patent Approvals
Competitive Landscape
Slide 34: Porter’s Five Forces Analysis
Slide 35: Public Trading Comparables, Top 3 Companies
Slide 36-38: Competitive Benchmarking, Key Ratios of Top 3 Companies – Operational Basis (FY 2013)
Slide 39: Competitive Benchmarking, Key Ratios of Top 3 Companies – Financial Basis (FY 2013)
Slide 40-75: Major Public Players
Slide 76-85: major Private Players
Recent Developments
Slide 86-87: Recent Developments
Strategic Recommendation
Slide 88: Strategic recommendation
Appendix
Slide 89: Key Ratios Description
Slide 90: Sources of Information
